Clinical trials: Resolution
Neurotrophic Keratitis
A Phase II Study of STSP-0902 Ophthalmic Solution in Patients With Neurotrophic Keratitis
This is a Phase II, double-blind, placebo-controlled study to evaluate the safety and efficacy of STSP-0902 ophthalmic solution in patients with neurotrophic keratitis (NK).
- Trial name
- NCT06975748
- Testing
- STSP-0902 ophthalmic solution
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Staidson (Beijing) Biopharmaceuticals Co., Ltd
Endoscopic Mucosal Resection, Colonic Neoplasms
Efficacy and Safety of a Solution for Endoscopic Mucosal Resection of Colonic Lesions
The objetive of this clinical trial is to evaluate the efficacy and safety of a solution for endoscopic mucosal resection of colonic lesions in patients undergoing endoscopic resection procedures.
- Conditions
- Endoscopic Mucosal Resection, Colonic Neoplasms, Therapeutic Irrigation, Treatment Outcome
- Trial name
- NCT06910514
- Testing
- Mucopolysaccharide saline solution 0.9%, Saline solution 0.9%
- Where
- Spain
- Volunteers
- 52 people
- Sponsor
- Nakafarma S.L.
Hypotension
Efficacy of Voluven® for the Prevention of Hypotension During Spinal Anesthesia for Cesarean Section
The aim of the study is to evaluate the efficacy of Voluven® in the prevention of maternal hypotension in women undergoing spinal anesthesia for cesarean section
- Trial name
- CAESAR (NCT00694343)
- Testing
- HES 130/0.4 (6%) in sodium chloride (solution for infusion), Ringer's Lactate solution
- Where
- 14 sites in France
- Volunteers
- 167 people
- Sponsor
- Fresenius Kabi
Acanthamoeba Keratitis
Safety and Tolerability of Preservative-free Polyhexamethylene Biguanide (PHMB) Ophthalmic Solution in Healthy Subjects
Randomized, double-masked, placebo-controlled, multiple center, parallel-group Phase 1 study to evaluate the safety and tolerability of 3 doses of preservative-free PHMB ophthalmic solution compared to placebo in healthy subjects
- Trial name
- NCT02506257
- Testing
- 0.04% PHMB, 0.06% PHMB, 0.08% PHMB
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- SIFI SpA
Periodontal Disease
Assessment of the Efficacy and Safety of OROXID® Oral Solution in Patients With Periodontitis
Periodontitis is a chronic, irreversible inflammatory disease affecting the supporting structures of the teeth. It is most commonly caused by bacteria in dental plaque, also known as biofilm.
- Trial name
- OroxParodont (NCT07257887)
- Testing
- OROXID® forte oral solution, OROXID® sensitive oral solution, Standard of Care
- Where
- 2 sites in Slovenia
- Volunteers
- 90 people
- Sponsor
- ENIKAM d.o.o.
Pulmonary Fungal Infection
An Efficacy and Safety Study of Itraconazole Sequential Therapy (Intravenous Injection Followed by Oral Solution) in Invasive Pulmonary Fungal Infections
The purpose of this study is to evaluate the efficacy and safety of itraconazole sequential therapy (intravenous injection/oral solution) in participants with invasive pulmonary fungal infections ([IPFI]; lung diseases caused by…
- Trial name
- NCT01823289
- Testing
- Itraconazole
- Volunteers
- 71 people
- Sponsor
- Xian-Janssen Pharmaceutical Ltd.
Open-Angle Glaucoma, Ocular Hypertension
Safety and Efficacy Study of DE-104 Ophthalmic Solution to Treat Open-angle Glaucoma or Ocular Hypertension
To investigate the dose-response relationship of DE-104 ophthalmic solution in lowering intraocular pressure (IOP) in subjects with Primary Open-Angle Glaucoma or Ocular Hypertension
- Trial name
- NCT00650338
- Testing
- DE-104 ophthalmic solution, low concentration, DE-104 ophthalmic solution, medium concentration, DE-104 ophthalmic solution, high concentration
- Where
- 14 sites in United States
- Volunteers
- 165 people
- Sponsor
- Santen Inc.
Cataracts
VIGADEXA Gel Compared to VIGADEXA Solution Following Cataract Surgery
The purpose of this study is to compare VIGADEXA (moxifloxacin 0.5%/dexamethasone phosphate 0.075%) ophthalmic gel to VIGADEXA (moxifloxacin 0.5%/dexamethasone phosphate 0.1%) ophthalmic solution in the prevention of…
- Trial name
- NCT01515826
- Testing
- Moxifloxacin 0.5%/Dexamethasone Phosphate 0.075% Ophthalmic Gel (VIGADEXA Gel), Moxifloxacin 0.5%/Dexamethasone Phosphate 0.1% Ophthalmic Solution (VIGADEXA Solution)
- Sponsor
- Alcon Research
Cataract
Safety and Efficacy Study of an Ophthalmic Solution in Patients With Age-Related Cataract
The purpose of this study is to determine the safety and efficacy of C-KAD Ophthalmic Solution in improving visual acuity relative to placebo in patients with age-related cataract
- Trial name
- NCT00793091
- Testing
- C-KAD Ophthalmic Solution
- Where
- 4 sites in United States
- Volunteers
- 80 people
- Sponsor
- Chakshu Research, Inc.
Postherpetic Neuralgia
Civamide Nasal Solution for Postherpetic Neuralgia of the Trigeminal Nerve
Herpes zoster (commonly referred to as "shingles") results from the reactivation of the varicella-zoster virus acquired during a primary infection, usually chickenpox.
- Trial name
- NCT01886313
- Testing
- Civamide Nasal Spray
- Where
- 5 sites in United States
- Volunteers
- 11 people
- Sponsor
- Winston Laboratories
Open Angle Glaucoma, Ocular Hypertension
DE-111 Against Tafluprost Ophthalmic Solution 0.0015% Alone and Concomitant Use of Tafluprost Ophthalmic Solution 0.0015% Plus Timolol Ophthalmic Solution 0.5%
DE-111 ophthalmic solution will be evaluated for superiority in comparison with Tafluprost 0.0015% ophthalmic solution, or for non-inferiority in comparison with Tafluprost 0.0015% and Timolol ophthalmic solution 0.5% used…
- Trial name
- NCT01342081
- Testing
- DE-111 ophthalmic solution, Tafluprost ophthalmic solution 0.0015%, Concomitant use of tafluprost ophthalmic solution 0.0015% plus timolol ophthalmic solution 0.5%
- Where
- Japan
- Volunteers
- 489 people
- Sponsor
- Santen Pharmaceutical Co., Ltd.
Onychomycosis
Safety and Pharmacokinetics of Efinaconazole Topical Solution in Subjects With Mild to Severe Onychomycosis
Safety and Pharmacokinetics (PK) of a once daily topical application of efinaconazole in the treatment of pediatric subjects with mild to severe onychomycosis of the toenails.
- Trial name
- NCT02812771
- Testing
- Efinaconazole
- Where
- 10 sites in United States, Dominican Republic
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Bausch Health Americas, Inc.
COPD
A Trial to Evaluate the Efficacy and Safety of Formoterol Fumarate in the Treatment of Patients With COPD
The purpose of this study is to determine the safety and efficacy of the investigational drug in comparison with a placebo.
- Trial name
- NCT00215436
- Testing
- Formoterol Fumarate
- Where
- 44 sites in United States
- Volunteers
- 345 people
- Sponsor
- Dey
Dry Eye Disease
Study to Assess Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of Palovarotene Ophthalmic Solution in Healthy Adult Subjects
Dry eye disease (DED) is a keratoconjunctive disorder that "is a multifactorial disease of the tears and ocular surface that results in symptoms of discomfort, visual disturbance, and tear film instability with potential damage…
- Trial name
- NCT04762355
- Testing
- Palovarotene, Vehicle
- Where
- Canada
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Clementia Pharmaceuticals Inc.
Alopecia Areata, Alopecia Totalis
Open Label Study of ATI-50002 Topical Solution Administered to Adult Subjects With Eyebrow Loss Due to Alopecia Areata
The main objective of this study is to assess the safety, tolerability and efficacy of ATI-50002 Topical Solution in subjects with unilateral or bilateral loss of eyebrow hair due to alopecia areata (AA), alopecia universalis…
- Conditions
- Alopecia Areata, Alopecia Totalis, Alopecia Universalis
- Trial name
- NCT03551821
- Testing
- ATI-50002
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Aclaris Therapeutics, Inc.
Glaucoma, Open-Angle
Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% to LUMIGAN® In The Treatment of Chronic Open-Angle Glaucoma
This is a randomized, double-masked, two-treatment, single-period, parallel design, multiple dose at multiple clinical trial sites designed to demonstrate bioequivalence with clinical endpoint in subjects with chronic open-angle…
- Trial name
- Glaucoma (NCT04890106)
- Testing
- Test - Bimatoprost 0.01% Ophthalmic Solution, Reference - LUMIGAN® (Bimatoprost 0.01% Ophthalmic Solution)
- Where
- 9 sites in United States
- Volunteers
- 310 people
- Sponsor
- Mankind Pharma Limited
Bacterial Conjunctivitis
AL-15469A for the Treatment of Bacterial Conjunctivitis
The purpose of the study is to determine whether AL-15469A is safe and effective in the treatment of bacterial conjunctivitis.
- Trial name
- NCT00332293
- Testing
- Moxifloxacin Alternative Formulation Ophthalmic Solution 0.5%, Moxifloxacin hydrochloride ophthalmic solution 0.5% as base
- Where
- United States
- Volunteers
- 695 people
- Sponsor
- Alcon Research
Pulmonary Disease, Chronic Obstructive
Efficacy and Safety Comparison of Tiotropium Inhalation Solution (Respimat Inhaler) and Spiriva HandiHaler in COPD
Non-inferiority of lung function response to Tiotropium inhalation solution compared to Spiriva HandiHaler
- Trial name
- NCT00239447
- Testing
- Tiotropium, HandiHaler, Respimat SMI
- Where
- 11 sites in United States, Canada
- Volunteers
- 131 people
- Sponsor
- Boehringer Ingelheim
Open Angle Glaucoma
A Phase 1b Study of ONL1204 Ophthalmic Solution in Patients with Progressing Open Angle Glaucoma
The purpose of this study is to demonstrate the safety and tolerability of ONL1204 Ophthalmic Solution in patients with progressing open angle glaucoma.
- Trial name
- NCT05160805
- Testing
- ONL1204 Ophthalmic solution (Dose A), ONL1204 Ophthalmic solution (Dose B)
- Where
- 11 sites in Australia, New Zealand
- Volunteers
- 25 people
- Sponsor
- ONL Therapeutics
Pulmonary Disease, Chronic Obstructive
12 Week Comparison of 5 Mcg and 10 Mcg of Tiotropium / Respimat, Placebo and Ipratropium MDI in COPD
The primary objective was to compare the bronchodilator efficacy of two doses (5 mcg and 10 mcg) of tiotropium inhalation solution delivered by the Respimat inhaler once daily to placebo and to ipratropium bromide MDI four times…
- Trial name
- NCT00239473
- Testing
- 5 mcg once daily tiotropium inhalation solution delivered by the Respimat inhaler, 10 mcg once daily tiotropium inhalation solution delivered by the Respimat inhaler
- Where
- 38 sites in Germany, Italy and 2 more
- Volunteers
- 429 people
- Sponsor
- Boehringer Ingelheim
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.